Samsung BioLogics Co (XKRX:207940) Insider Ownership : 0.00 % (As of May. 13, 2025)

View and export this data going back to 2016. Start your Free Trial

What is Samsung BioLogics Co Insider Ownership?

Insider ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Samsung BioLogics Co's insider ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Samsung BioLogics Co's Institutional Ownership is 8.13%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Samsung BioLogics Co's Float Percentage Of Total Shares Outstanding is 0.00%.

Samsung BioLogics Co Insider Ownership Historical Data

The historical data trend for Samsung BioLogics Co's Insider Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Samsung BioLogics Co Insider Ownership Chart

Samsung BioLogics Co Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Insider Ownership

Get a 7-Day Free Trial

Samsung BioLogics Co Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Insider Ownership	Get a 7-Day Free Trial															-	-	-	-	-

Samsung BioLogics Co Insider Ownership Calculation

The percentage of shares that are owned by company insiders relative to the total shares outstanding.

Samsung BioLogics Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Samsung BioLogics Co Ltd (XKRX:207940) » Definitions » Insider Ownership

Comparable Companies

Traded in Other Exchanges

N/A

Address

125, Cheomdan-daero, Yeonsu-gu, Incheon, KOR

Website

https://www.samsungbiologics.com

Founded in 2011, Samsung Biologics is a South Korean contract development and manufacturing organization with a global client base. Europe and the US contribute 90% of its total revenue. It provides end-to-end development and manufacturing services from cell line developments to final commercial manufacturing. As of 2023, Samsung Biologics had a total production capacity of 604,000 liters, one of the largest in the world. Its CDMO services account for 72.4% of its total revenue. The balance comes from subsidiary Samsung Bioepis, acquired in 2022. Samsung Bioepis is involved in developing and manufacturing biosimilars.

Samsung BioLogics Co Headlines

No Headlines